CARDIOVASCULAR DRUGS AND THERAPY

Scope & Guideline

Elevating standards in cardiovascular drug therapy.

Introduction

Delve into the academic richness of CARDIOVASCULAR DRUGS AND THERAPY with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN0920-3206
PublisherSPRINGER
Support Open AccessNo
CountryNetherlands
TypeJournal
Convergefrom 1987 to 2024
AbbreviationCARDIOVASC DRUG THER / Cardiovasc. Drugs Ther.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressVAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS

Aims and Scopes

The journal "Cardiovascular Drugs and Therapy" focuses on the pharmacological aspects of cardiovascular diseases and therapies, emphasizing the efficacy, safety, and mechanisms of various cardiovascular drugs. It serves as a critical platform for disseminating research findings that explore drug interactions, treatment outcomes, and innovative therapeutic strategies in the field of cardiovascular medicine.
  1. Pharmacotherapy in Cardiovascular Diseases:
    The journal discusses various pharmacological treatments for cardiovascular diseases, including antiplatelet agents, anticoagulants, lipid-lowering drugs, and antihypertensives, analyzing their efficacy, safety, and clinical implications.
  2. Clinical Trials and Meta-analyses:
    It publishes results from clinical trials and meta-analyses that evaluate the effectiveness of new and existing cardiovascular therapies, providing evidence-based insights for clinicians and researchers.
  3. Mechanisms of Cardiovascular Drugs:
    Research on the underlying mechanisms of action of cardiovascular drugs is a focus area, exploring how these drugs interact at the molecular and cellular levels to influence cardiovascular health.
  4. Innovative Therapeutic Strategies:
    The journal highlights novel approaches to cardiovascular treatment, including the development of new drug formulations, combination therapies, and the use of genetic and biomarker information to tailor treatments.
  5. Real-World Evidence and Pharmacovigilance:
    It emphasizes the importance of real-world data and pharmacovigilance studies in understanding the long-term safety and effectiveness of cardiovascular therapies, informing clinical practice.
The journal "Cardiovascular Drugs and Therapy" has identified several emerging trends and themes that reflect the evolving landscape of cardiovascular research and therapy. These topics are gaining traction and are likely to shape future research directions.
  1. Precision Medicine in Cardiovascular Therapy:
    There is a growing focus on precision medicine approaches, including pharmacogenomics, that tailor cardiovascular treatments based on individual genetic and molecular profiles to enhance efficacy and safety.
  2. Role of SGLT2 Inhibitors:
    SGLT2 inhibitors have become a significant area of research, with numerous studies exploring their cardiovascular benefits beyond glycemic control, particularly in heart failure and renal protection.
  3. Anticoagulation Strategies in Atrial Fibrillation:
    Research into optimizing anticoagulation strategies for atrial fibrillation patients is trending, particularly regarding the comparative effectiveness of direct oral anticoagulants versus traditional therapies.
  4. Cardiovascular Impacts of Diabetes Medications:
    The intersection of diabetes management and cardiovascular health is increasingly prominent, with studies examining the cardiovascular effects of GLP-1 receptor agonists and other diabetes medications.
  5. Long-term Outcomes of Cardiovascular Interventions:
    There is an emerging emphasis on the long-term outcomes of various cardiovascular interventions, including surgical and catheter-based procedures, highlighting the importance of sustained patient follow-up.

Declining or Waning

While many areas continue to thrive, certain themes in the journal "Cardiovascular Drugs and Therapy" have shown a declining interest or frequency of publication. These waning scopes may reflect shifts in research priorities or advancements in the field that have rendered some topics less relevant.
  1. Traditional Antihypertensive Therapies:
    There appears to be a reduction in studies focusing solely on traditional antihypertensive medications, as newer classes of drugs and combination therapies gain prominence in clinical practice.
  2. Single-Agent Studies:
    Research focused exclusively on single-agent therapies is declining, with a noticeable shift towards combination therapies and multi-drug regimens that reflect contemporary clinical practice.
  3. Pharmacokinetics of Established Drugs:
    There is less emphasis on the pharmacokinetics of well-established cardiovascular drugs, as research increasingly prioritizes new therapeutic agents and innovative treatment strategies.
  4. Animal Model Studies:
    The prevalence of studies using traditional animal models to evaluate drug efficacy is decreasing, potentially due to a growing focus on human clinical trials and translational research.
  5. Generalized Risk Factor Studies:
    Research that broadly addresses cardiovascular risk factors without a direct link to specific therapeutic interventions is diminishing, as the emphasis shifts towards targeted therapeutic approaches.

Similar Journals

Expert Review of Cardiovascular Therapy

Empowering Clinicians with Cutting-edge Cardiovascular Research
Publisher: TAYLOR & FRANCIS INCISSN: 1477-9072Frequency: 12 issues/year

Expert Review of Cardiovascular Therapy is a leading academic journal published by TAYLOR & FRANCIS INC, focusing on innovative and impactful research in the field of cardiovascular medicine. With an ISSN of 1477-9072 and an E-ISSN of 1744-8344, this journal serves as an essential resource for researchers, clinicians, and educators, offering a platform for the dissemination of critical advancements in cardiovascular therapy and internal medicine. Since its inception in 2003, the journal has maintained a reputable standing with a Q2 ranking in various categories including Cardiology and Cardiovascular Medicine, reflecting its influence and rigor in the field. The journal, which is based in the United Kingdom, does not currently offer Open Access options, ensuring that its content is accessible primarily to subscribers. With its commitment to high-quality, peer-reviewed articles, Expert Review of Cardiovascular Therapy is dedicated to bridging the gap between experimental research and clinical application, thereby enhancing patient care and therapeutic outcomes in cardiovascular health.

CARDIOVASCULAR RESEARCH

Connecting research to real-world cardiovascular solutions.
Publisher: OXFORD UNIV PRESSISSN: 0008-6363Frequency: 18 issues/year

CARDIOVASCULAR RESEARCH, published by Oxford University Press, is a premier academic journal dedicated to the evolving field of cardiology and cardiovascular medicine. With a remarkable impact factor reflecting its significant contribution to the scientific community, this journal maintains a Q1 ranking in both Cardiology and Physiology categories, demonstrating its commitment to publishing high-quality research that influences clinical practices and healthcare outcomes. Established in 1967, the journal has consistently provided a platform for innovative studies and reviews, aiming to advance our understanding of cardiovascular physiology and pathology. Researchers, professionals, and students will find published articles crucial for their work, as the journal covers a broad spectrum of topics including molecular biology, genetics, and clinical studies. While currently not offering open access options, CARDIOVASCULAR RESEARCH remains accessible through institutional and individual subscriptions, ensuring that the latest findings are available to those in the cardiovascular science community.

Anatolian Journal of Cardiology

Exploring Innovative Pathways in Cardiovascular Medicine.
Publisher: KARE PUBLISSN: 2149-2263Frequency: 12 issues/year

The Anatolian Journal of Cardiology, published by KARE PUBL, stands as a vital resource in the field of Cardiology and Cardiovascular Medicine. With an ISSN of 2149-2263 and E-ISSN 2149-2271, this Open Access journal has been fostering the dissemination of critical research since 2001, ensuring that high-quality content is freely available to a global audience. Based in Turkey, the journal aims to bridge gaps in cardiological knowledge through rigorous peer-reviewed articles that span a wide range of topics, from innovative clinical practices to groundbreaking research findings. While its current ranking places it in the Q3 category of cardiology journals, the Anatolian Journal of Cardiology continues to strive towards enhancing its impact, currently holding a Scopus rank of 236 out of 387. Researchers, practitioners, and students alike will find this journal an essential platform for keeping abreast of the latest developments in cardiovascular health.

Archives of Cardiovascular Diseases

Transforming the future of cardiology with innovative insights.
Publisher: ELSEVIER MASSON, CORP OFFISSN: 1875-2136Frequency: 12 issues/year

The Archives of Cardiovascular Diseases, published by Elsevier Masson, stands as a leading journal in the field of cardiology and cardiovascular medicine, with an impressive impact factor that underscores its relevance and influence. This esteemed journal, recognized in the Q2 category for both cardiology and miscellaneous medicine, aims to disseminate groundbreaking research, innovative methodologies, and clinical advancements that can shape the future of cardiovascular health. With its diverse array of open access options, researchers and students alike have the ability to engage with high-quality content, ensuring that cutting-edge findings are accessible globally. Since its inception in 2008, the journal has actively contributed to the advancement of knowledge in cardiovascular diseases, fostering collaboration among clinicians, researchers, and educators. Headquartered in Paris, France, Archives of Cardiovascular Diseases remains committed to enhancing our understanding of cardiovascular health and improving patient outcomes worldwide.

Current Vascular Pharmacology

Exploring the Frontiers of Cardiovascular Pharmacology
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1570-1611Frequency: 6 issues/year

Current Vascular Pharmacology is a premier academic journal published by Bentham Science Publications Ltd, focusing on the intersection of pharmacology and cardiovascular medicine. With an impact factor that reflects its significance in the field, this journal ranks in the Q1 category for both Pharmacology and Cardiology, showcasing its dedication to high-quality research. Its Scopus ranks place it in the top percentile of its categories, highlighting its influence among scholars and practitioners alike. Issued since 2003 and continuing through 2024, Current Vascular Pharmacology aims to disseminate cutting-edge findings and foster knowledge exchange among researchers, professionals, and students engaged in cardiovascular pharmacology. Despite being a subscription-based journal, it remains a vital resource for those seeking the latest advancements in drug development and therapeutic interventions for vascular diseases. Located in the United Arab Emirates, the journal serves as an essential platform for global discourse on vascular health.

BASIC RESEARCH IN CARDIOLOGY

Driving innovation in cardiac research and clinical practice.
Publisher: SPRINGER HEIDELBERGISSN: 0300-8428Frequency: 6 issues/year

BASIC RESEARCH IN CARDIOLOGY, published by SPRINGER HEIDELBERG, is an esteemed peer-reviewed journal dedicated to advancing the field of cardiology and cardiovascular medicine since 1973. With a strong emphasis on the latest breakthroughs in basic and translational research, this journal offers a platform for high-quality, impactful studies that contribute to our understanding of cardiac function and related physiological processes. Currently ranked in the Q1 category in Cardiology and Cardiovascular Medicine, as well as Physiology and Medical Physiology, BASIC RESEARCH IN CARDIOLOGY is recognized as a leading journal within these disciplines, boasting impressive Scopus ranks that place it in the top tiers of global research output. While it does not offer open access, its contributions are pivotal for researchers, clinicians, and students seeking to stay abreast of cutting-edge discoveries and methodologies in cardiovascular science. With its commitment to scholarly excellence, this journal plays a critical role in shaping the future of cardiac research and clinical practice.

COR ET VASA

Connecting researchers and clinicians for a healthier heart.
Publisher: CZECH SOC CARDIOLOGY & CZECH SOC CARDIOVASCULAR SURGERYISSN: 0010-8650Frequency: 6 issues/year

COR ET VASA is a prominent peer-reviewed journal in the field of cardiology and cardiovascular medicine, published by the Czech Society of Cardiology and Czech Society of Cardiovascular Surgery. Established in 1961, and continuing its legacy from 2006 to 2024, this journal serves as an essential platform for disseminating significant research findings, clinical studies, and innovative treatments in cardiovascular health. While currently positioned in the Q4 quartile, the journal aims to enhance its impact by fostering knowledge sharing among researchers, clinicians, and students alike. The journal, with its publication in Czech Republic, provides a unique perspective to the European cardiovascular community, allowing for invaluable insights and discourse. Researchers are encouraged to submit their manuscripts and contribute to the growing body of knowledge in this critical area, although it should be noted that COR ET VASA does not offer open access options at this time. As the field of cardiovascular medicine evolves, COR ET VASA remains committed to addressing the latest challenges and advancements, nurturing a rich dialogue within the community.

European Journal of Preventive Cardiology

Connecting researchers to advance cardiovascular prevention.
Publisher: OXFORD UNIV PRESSISSN: 2047-4873Frequency: 18 issues/year

The European Journal of Preventive Cardiology, published by Oxford University Press, is a leading international journal dedicated to the field of cardiology and cardiovascular medicine. With an impact factor that underscores its prestige—ranking in the top quartile (Q1) of both cardiology and epidemiology categories—the journal serves as a critical resource for researchers and practitioners seeking to advance their understanding of preventive strategies in cardiovascular health. Since its inception in 1999, it has provided a platform for high-quality research and reviews that address the epidemiology of cardiovascular diseases, risk factor management, and innovative prevention methodologies. Notably, it currently ranks #21 out of 387 in Medicine - Cardiology and #13 out of 148 in Medicine - Epidemiology according to Scopus, highlighting its influential position in these essential biomedical fields. The journal also provides open access options, allowing both readers and authors the opportunity to engage with groundbreaking research and enhance the dissemination of knowledge. With a commitment to excellence, the European Journal of Preventive Cardiology is an invaluable asset for those dedicated to the prevention of cardiovascular diseases.

Journal of the Practice of Cardiovascular Sciences

Elevating Standards in Cardiovascular Research and Practice
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2395-5414Frequency: 3 issues/year

Journal of the Practice of Cardiovascular Sciences, published by Wolters Kluwer Medknow Publications, is an esteemed Open Access journal dedicated to advancing knowledge in the field of cardiovascular health. With its ISSN 2395-5414 and E-ISSN 2454-2830, the journal serves as a vital platform for researchers, healthcare professionals, and students to disseminate and access high-quality studies, innovations, and practical applications related to cardiovascular sciences. Established in 2015 as an Open Access journal, it promotes widespread sharing of insights to enhance cardiovascular practices and address contemporary challenges in the field. As part of a reputable publishing group, the journal is poised for growth and impact, contributing significantly to the ongoing dialogue in cardiovascular research and clinical practice.

Clinica e Investigacion en Arteriosclerosis

Pioneering research that shapes the future of cardiology.
Publisher: ELSEVIERISSN: 0214-9168Frequency: 6 issues/year

Clinica e Investigacion en Arteriosclerosis is a premier academic journal dedicated to the field of cardiology and cardiovascular medicine, published by ELSEVIER. With its ISSN 0214-9168 and E-ISSN 1578-1879, the journal aims to disseminate high-quality research and innovations in the understanding and treatment of arterial diseases, contributing significantly to both clinical practices and pharmacological advancements. Established in 2007 and continuing into 2024, the journal has garnered recognition with a notable Q3 categorization in both Cardiology and Cardiovascular Medicine and Pharmacology (medical) for 2023, reflecting its impact in the academic community. Researchers and healthcare professionals utilizing this journal will find a diverse range of articles exploring novel therapeutic strategies and epidemiological data, making it an essential resource for advancing knowledge and practice in cardiovascular health. While it does not operate as an open-access journal, the findings published in Clinica e Investigacion en Arteriosclerosis are pivotal for understanding current trends and future directions in cardiovascular research.